Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.
T cells
animal model
checkpoint inhibitors
cytokines
immunotherapy
mucormycosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
12
2021
accepted:
02
02
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Anecdotal clinical reports suggested a benefit of adjunct immune checkpoint inhibitors (ICIs) to treat invasive mucormycosis. However, proof-of-concept data in animal models and mechanistic insights into the effects of ICIs on host defense against Mucorales are lacking. Therefore, we studied the effects of PD-1 and PD-L1 inhibitors (4 doses of 250 µg/kg) on outcomes and immunopathology of invasive pulmonary mucormycosis (IPM) in cyclophosphamide- and cortisone acetate-immunosuppressed mice.
Identifiants
pubmed: 35251033
doi: 10.3389/fimmu.2022.838344
pmc: PMC8896628
doi:
Substances chimiques
B7-H1 Antigen
0
Cytokines
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
838344Informations de copyright
Copyright © 2022 Wurster, Albert, Bharadwaj, Kasembeli, Tarrand, Daver and Kontoyiannis.
Déclaration de conflit d'intérêts
DK reports honoraria and research support from Gilead Sciences and Astellas Pharma. He received consultant fees from Astellas Pharma, Merck, and Gilead Sciences, and is a member of the Data Review Committee of Cidara Therapeutics, AbbVie, Scynexis, and the Mycoses Study Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Trends Mol Med. 2019 Dec;25(12):1080-1093
pubmed: 31494023
Clin Infect Dis. 2008 Jul 15;47(2):226-35
pubmed: 18540822
Lancet Oncol. 2017 Dec;18(12):1571-1573
pubmed: 29208429
Intensive Care Med Exp. 2018 Jul 27;6(1):20
pubmed: 30054760
Clin Microbiol Infect. 2012 Feb;18(2):134-9
pubmed: 22044625
J Exp Med. 2014 May 5;211(5):943-59
pubmed: 24752301
Cold Spring Harb Perspect Med. 2014 Nov 06;5(3):a019612
pubmed: 25377140
Ann Oncol. 2016 Jul;27(7):1190-8
pubmed: 26912558
Front Immunol. 2020 Jul 07;11:1508
pubmed: 32733486
J Fungi (Basel). 2021 Apr 15;7(4):
pubmed: 33920755
J Infect Dis. 2020 Aug 17;222(6):989-994
pubmed: 32432714
Mol Microbiol. 2010 Aug;77(3):587-604
pubmed: 20545847
PLoS One. 2010 Sep 23;5(9):e12955
pubmed: 20886035
Mycoses. 2014 Dec;57 Suppl 3:40-7
pubmed: 25175306
Infect Immun. 2014 Jun;82(6):2649-56
pubmed: 24711569
Front Microbiol. 2018 Jul 25;9:1612
pubmed: 30090091
PLoS One. 2016 Feb 12;11(2):e0149108
pubmed: 26871570
Eur J Immunol. 2003 Oct;33(10):2706-16
pubmed: 14515254
J Nucl Med. 2019 Sep;60(9):1317-1324
pubmed: 30796172
Antimicrob Agents Chemother. 2010 Mar;54(3):1298-304
pubmed: 20038620
Shock. 2011 Jul;36(1):38-44
pubmed: 21368717
Hemasphere. 2021 Feb 10;5(3):e530
pubmed: 33604513
J Fungi (Basel). 2018 Dec 14;4(4):
pubmed: 30558125
Front Immunol. 2017 Dec 04;8:1597
pubmed: 29255458
J Fungi (Basel). 2021 Jun 06;7(6):
pubmed: 34204025
Front Microbiol. 2019 Jan 08;9:3204
pubmed: 30671036
J Immunol. 2009 Apr 15;182(8):4938-46
pubmed: 19342673
J Infect Dis. 2017 Dec 5;216(10):1281-1294
pubmed: 28968869
Interdiscip Perspect Infect Dis. 2014;2014:562610
pubmed: 25210515
Clin Immunol. 2021 Aug;229:108742
pubmed: 33905818
J Infect Dis. 2012 Jul 1;206(1):135-9
pubmed: 22529315
J Fungi (Basel). 2020 Sep 17;6(3):
pubmed: 32957440
Mol Ther Methods Clin Dev. 2018 Mar 14;9:305-312
pubmed: 30038934
Cytotherapy. 2016 Jan;18(1):65-79
pubmed: 26552765
Shock. 2020 Apr;53(4):514-524
pubmed: 31306346
Lancet Infect Dis. 2017 Jan;17(1):18
pubmed: 27998559
PLoS One. 2020 Jun 17;15(6):e0234063
pubmed: 32555589
iScience. 2020 Dec 24;24(1):101960
pubmed: 33437940
Sci Rep. 2019 Aug 7;9(1):11472
pubmed: 31391510
Med Microbiol Immunol. 2020 Oct;209(5):579-592
pubmed: 32236695
J Fungi (Basel). 2017 Oct 04;3(4):
pubmed: 29371571
Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34
pubmed: 22247442
Cells. 2021 Sep 06;10(9):
pubmed: 34571982
Antimicrob Agents Chemother. 2005 Feb;49(2):721-7
pubmed: 15673756
Curr Oncol Rep. 2020 Nov 3;22(12):126
pubmed: 33141349
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2658-63
pubmed: 18268348
mBio. 2019 May 28;10(3):
pubmed: 31138745
Antimicrob Agents Chemother. 2008 Feb;52(2):722-4
pubmed: 18025115
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
Virulence. 2017 Nov 17;8(8):1708-1718
pubmed: 28783439